NeoVista Rolls Out Novel Treatment for AMD Using Radiation
November 17, 2009
Submit Comments
NeoVista’s Vidion ANV Therapy System has now been used in patients in Europe.
This novel system involves brachytherapy, or radiation, to treat patients with wet macular degeneration. The device delivers a single dose of strontium-90 beta ionizing radiation to the retina.
Neovista is hopeful that this will be a successful alternative to repeated intraocular injections. The Vidion system is anticipating Phase III trials soon.
You might also enjoy...
- NeoVista Raises $18 Million to Fund Continued Clinical Trials of Beta Radiation Therapy for Wet AMD
- More on the NeoVista Epi-Retinal Strontium 90 Treatment for Wet AMD
- FDA Grants NeoVista’s Request to Utilize Novel Wet AMD Treatment in Compassionate Case
- NeoVista®, Inc. Completes Enrollment in Pivotal CABERNET™ Study
- Adjunctive Therapy for Intravitreal Injections for ARMD
Comments
Jump down to form below to submit your own comments
Subscribe for Free!
